Primecap Management
BBIO icon

Primecap Management’s BridgeBio Pharma BBIO Stock Holding History

Primecap Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$75.7M Buy
1,015,980
+446,800
+78% +$31.3M 0.04% 174
2026
Q1 		$42.3M Sell
569,180
-500
-0.1% -$36.2K 0.03% 199
2025
Q4 		$43.6M Sell
569,680
-6,690
-1% -$439K 0.03% 198
2025
Q3 		$29.9M Sell
576,370
-12,340
-2% -$602K 0.02% 224
2025
Q2 		$25.4M Sell
588,710
-324,490
-36% -$11.8M 0.02% 230
2025
Q1 		$31.6M Sell
913,200
-2,300
-0.3% -$77.6K 0.03% 207
2024
Q4 		$25.1M Buy
915,500
+8,776
+1% +$227K 0.02% 228
2024
Q3 		$23.1M Sell
906,724
-20,176
-2% -$530K 0.02% 226
2024
Q2 		$23.5M Sell
926,900
-330
-0% -$9.02K 0.02% 224
2024
Q1 		$28.7M Sell
927,230
-16,770
-2% -$570K 0.02% 220
2023
Q4 		$38.1M Buy
944,000
+5,300
+0.6% +$159K 0.03% 199
2023
Q3 		$24.8M Buy
938,700
+242,608
+35% +$6.88M 0.02% 216
2023
Q2 		$12M Sell
696,092
-43,900
-6% -$661K 0.01% 251
2023
Q1 		$12.3M Sell
739,992
-173,300
-19% -$2.02M 0.01% 245
2022
Q4 		$6.96M Sell
913,292
-124,438
-12% -$1.19M 0.01% 263
2022
Q3 		$10.3M Sell
1,037,730
-15,100
-1% -$157K 0.01% 249
2022
Q2 		$9.56M Sell
1,052,830
-79,520
-7% -$665K 0.01% 254
2022
Q1 		$11.5M Buy
1,132,350
+81,610
+8% +$838K 0.01% 256
2021
Q4 		$17.5M Buy
1,050,740
+589,880
+128% +$25M 0.01% 248
2021
Q3 		$21.6M Buy
460,860
+14,000
+3% +$750K 0.02% 238
2021
Q2 		$27.2M Buy
446,860
+91,623
+26% +$5.23M 0.02% 230
2021
Q1 		$21.9M Buy
+355,237
New +$23.2M 0.02% 234

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Primecap Management's BBIO Position: Q2 2026 in Review

Primecap Management increased its BridgeBio Pharma (BBIO) stake by 78% in Q2 2026, buying an estimated $31.3M and bringing the position to 1,015,980 shares worth $75.7M. The position accounts for 0.04% of the portfolio, ranked #174.

Primecap Management first reported a position in BBIO in Q1 2021 and has held it in 22 quarters since. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Primecap Management held 1,015,980 shares of BridgeBio Pharma worth $75.7M as of Q2 2026.
  • Primecap Management bought 446,800 BridgeBio Pharma shares in Q2 2026, an estimated $31.3M.
  • BridgeBio Pharma made up 0.04% of Primecap Management's portfolio in Q2 2026, its #174 holding.
  • Primecap Management first reported a position in BridgeBio Pharma in Q1 2021 and has held it in 22 quarters since.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Primecap Management's 13F filing for Q2 2026, filed 14 Aug 2026.